96 related articles for article (PubMed ID: 25980295)
21. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
[TBL] [Abstract][Full Text] [Related]
22. [Biological function of endoecology (cleanliness of intercellular environment) realize two biolocical reactions: excretion reaction and inflammation reaction - utilization in vivo, in situ catabolites of the large molecular mass.].
Titov VN
Klin Lab Diagn; 2018; 63(11):668-676. PubMed ID: 30776199
[TBL] [Abstract][Full Text] [Related]
23. [Atherosclerosis as a problem of general biology: cell adaptation to deficiency of essential fatty acids].
Titov VN
Vestn Ross Akad Med Nauk; 1999; (10):53-7. PubMed ID: 10578666
[TBL] [Abstract][Full Text] [Related]
24. [The insulin initiates "kinetic perfection" of biologic function of locomotion. The glucose as substratum for synthesis of ω-9 oleic fatty acid by cross-striated miocytes.].
Titov VP; Sazhina NN; Aripovskiy AV; Evteeva NM
Klin Lab Diagn; 2016; 61(5):260-270. PubMed ID: 31529902
[TBL] [Abstract][Full Text] [Related]
25. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability.
Calder PC
Mol Nutr Food Res; 2012 Jul; 56(7):1073-80. PubMed ID: 22760980
[TBL] [Abstract][Full Text] [Related]
26. Hypolipidemic activity in Sprague-Dawley rats and constituents of a novel natural vegetable oil from Cornus wilsoniana fruits.
Fu J; Zhang XW; Liu K; Li QS; Zhang LR; Yang XH; Zhang ZM; Li CZ; Luo Y; He ZX; Zhu HL
J Food Sci; 2012 Aug; 77(8):H160-9. PubMed ID: 22747885
[TBL] [Abstract][Full Text] [Related]
27. Niacin in the prevention of atherosclerosis: Significance of vasodilatation.
Tuohimaa P; Järvilehto M
Med Hypotheses; 2010 Oct; 75(4):397-400. PubMed ID: 20452129
[TBL] [Abstract][Full Text] [Related]
28. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing.
Bourre JM
J Nutr Health Aging; 2004; 8(3):163-74. PubMed ID: 15129302
[TBL] [Abstract][Full Text] [Related]
29. Niacin stimulates adiponectin secretion through the GPR109A receptor.
Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
[TBL] [Abstract][Full Text] [Related]
30. New evidence for nicotinic acid treatment to reduce atherosclerosis.
Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
[TBL] [Abstract][Full Text] [Related]
31. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice.
Poupel L; Boissonnas A; Hermand P; Dorgham K; Guyon E; Auvynet C; Charles FS; Lesnik P; Deterre P; Combadiere C
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2297-305. PubMed ID: 23887641
[TBL] [Abstract][Full Text] [Related]
33. [Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids].
Villalobos ME; Sánchez-Muniz FJ; Acín MT; Vaquero MP; Higueras FJ; Bastida S
Nutr Hosp; 2010; 25(6):889-909. PubMed ID: 21519759
[TBL] [Abstract][Full Text] [Related]
34. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.
Dawczynski C; Massey KA; Ness C; Kiehntopf M; Stepanow S; Platzer M; Grün M; Nicolaou A; Jahreis G
Clin Nutr; 2013 Oct; 32(5):686-96. PubMed ID: 23332800
[TBL] [Abstract][Full Text] [Related]
35. Nicotinic acid: current status in lipid management and cardiovascular disease prevention.
Whayne TF
Angiology; 2014 Aug; 65(7):557-9. PubMed ID: 24101713
[No Abstract] [Full Text] [Related]
36. [Nicotinic acid: an unjustly neglected remedy].
Zák A; Zeman M; Vecka M; Tvrzická E
Cas Lek Cesk; 2006; 145(11):825-31. PubMed ID: 17168412
[TBL] [Abstract][Full Text] [Related]
37. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug?
Pike NB; Wise A
Curr Opin Investig Drugs; 2004 Mar; 5(3):271-5. PubMed ID: 15083592
[TBL] [Abstract][Full Text] [Related]
38. Emerging therapies for atherosclerosis prevention and management.
Chyu KY; Shah PK
Cardiol Clin; 2011 Feb; 29(1):123-35. PubMed ID: 21257104
[TBL] [Abstract][Full Text] [Related]
39. [Biology of essential fatty acids (EFA)].
Dobryniewski J; Szajda SD; Waszkiewicz N; Zwierz K
Przegl Lek; 2007; 64(2):91-9. PubMed ID: 17892040
[TBL] [Abstract][Full Text] [Related]
40. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
van den Hoek AM; van der Hoorn JW; Maas AC; van den Hoogen RM; van Nieuwkoop A; Droog S; Offerman EH; Pieterman EJ; Havekes LM; Princen HM
Diabetes Obes Metab; 2014 Jun; 16(6):537-44. PubMed ID: 24373179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
